Developing an asymptomatic mucosal herpes vaccine: the present and the future
- PMID: 20020824
- PMCID: PMC4512283
- DOI: 10.2217/fmb.09.101
Developing an asymptomatic mucosal herpes vaccine: the present and the future
References
-
- Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes and challenges from the battlefield. Expert Rev. Vaccines. 2009;8(8):426–437. ■■ Update of the most recent herpes simplex virus subunit vaccine development. - PMC - PubMed
-
- Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol. Res. 2006;36(1–3):119–126. - PubMed
-
- BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 2002;32(8):2274–2281. - PubMed
-
- BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines – yesterday, today, and tomorrow. Lancet Infect. Dis. 2002;2(7):425–431. ■ Describes the new concept of lipopeptide vaccine development. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources